Articles producció científica> Medicina i Cirurgia

Metformin administration induces hepatotoxic effects in paraoxonase-1-deficient mice

  • Identification data

    Identifier: PC:1546
    Handle: https://hdl.handle.net/20.500.11797/PC1546
    Authors:
    Jorge JovenAnabel García-HerediaMarta Riera-BorrullIsabel Fort-GallifaFedra Luciano-MateoNoemí CabréAnna Hernandez-AguileraJordi Camps
    Abstract:
    Metformin is the first-line pharmacological treatment of diabetes. In these patients, metformin reduces body weight and decreases the risk of diabetes-related complications such as cardiovascular disease. However, whether metformin elicits beneficial effects on liver histology is a controversial issue and, as yet, there is no consensus. Paraoxonase-1 (PON1), an enzyme synthesized mainly by the liver, degrades lipid peroxides and reduces oxidative stress. PON1 activities are decreased in chronic liver diseases. We evaluated the effects of metformin in the liver of PON1-deficient mice which, untreated, present a mild degree of liver steatosis. Metformin administration aggravated inflammation in animals given a standard mouse chow and in those fed a high-fat diet. Also, it was associated with a higher degree of steatosis in animals fed a standard chow diet. This report is a cautionary note regarding the prescription of metformin for the treatment of diabetes in patients with concomitant liver impairment.

  • Others:

    Author, as appears in the article.: Jorge Joven; Anabel García-Heredia; Marta Riera-Borrull; Isabel Fort-Gallifa; Fedra Luciano-Mateo; Noemí Cabré; Anna Hernandez-Aguilera; Jordi Camps
    Department: Medicina i Cirurgia
    URV's Author/s: JOVEN MARIED, JORGE; Anabel García-Heredia; Marta Riera-Borrull; Isabel Fort-Gallifa; Fedra Luciano-Mateo; Noemí Cabré; Anna Hernandez-Aguilera; CAMPS ANDREU, JORGE
    Keywords: metformin Paraoxonase Antioxidants
    Abstract: Metformin is the first-line pharmacological treatment of diabetes. In these patients, metformin reduces body weight and decreases the risk of diabetes-related complications such as cardiovascular disease. However, whether metformin elicits beneficial effects on liver histology is a controversial issue and, as yet, there is no consensus. Paraoxonase-1 (PON1), an enzyme synthesized mainly by the liver, degrades lipid peroxides and reduces oxidative stress. PON1 activities are decreased in chronic liver diseases. We evaluated the effects of metformin in the liver of PON1-deficient mice which, untreated, present a mild degree of liver steatosis. Metformin administration aggravated inflammation in animals given a standard mouse chow and in those fed a high-fat diet. Also, it was associated with a higher degree of steatosis in animals fed a standard chow diet. This report is a cautionary note regarding the prescription of metformin for the treatment of diabetes in patients with concomitant liver impairment.
    Research group: Unitat de Recerca Biomèdica
    Thematic Areas: Ciències de la salut Ciencias de la salud Health sciences
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 0009-2797
    Author identifier: orcid.org/0000-0003-2749-4541; N/D; N/D; N/D; N/D; N/D; N/D; N/D
    Record's date: 2016-05-24
    Last page: 63
    Journal volume: 249
    Papper version: info:eu-repo/semantics/acceptedVersion
    Link to the original source: https://www.sciencedirect.com/science/article/abs/pii/S0009279716300679
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Article's DOI: 10.1016/j.cbi.2016.03.004
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2016
    First page: 56
    Publication Type: Article Artículo Article

  • Keywords:

    Metformina
    Antioxidants
    Paraoxonasa
    metformin
    Paraoxonase
    Antioxidants
    Ciències de la salut
    Ciencias de la salud
    Health sciences
    0009-2797

  • Documents:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar